Alföldi A, Simkó K, Fekete M I, Farsang C
1st Department of Medicine, Tétényi Hospital, Budapest, Hungary.
Acta Physiol Hung. 1991;78(1):99-106.
The central alpha-2-adrenergic receptor agonist, clonidine (300 micrograms daily) significantly increased the plasma beta-endorphin-like immunoreactivity (beta ELI) in 12 patients with mild to moderate essential hypertension in a randomized, crossover study. A significant linear correlation between the increase in plasma beta ELI and the decrease in blood pressure (both systolic and diastolic) was found after clonidine administration. The role of the reduced central sympathetic tone, induced by alpha-2-adrenoceptor stimulation, in the elevation of circulating beta ELI can be suggested. The plasma beta ELI increased also significantly after the dopaminergic D-2 receptor agonist, bromocryptine treatment, (5 mg, daily) in 13 patients with borderline and mild essential hypertension in a randomized, crossover study. A significant drop in circulating noradrenaline and in arterial blood pressure and a significant linear correlation between the changes of plasma noradrenaline level and blood pressure was found after bromocryptine administration. There was no correlation between the rise in plasma beta ELI and the decrease in blood pressure after bromocryptine. The importance of the central sympathetic activity and not only a direct pituitary dopaminergic agonist effect on the beta-endorphin secretion can be stressed in the effect of bromocryptine on the immunoreactive beta-endorphin level.
在一项随机交叉研究中，中枢性α-2肾上腺素能受体激动剂可乐定（每日300微克）使12例轻至中度原发性高血压患者的血浆β-内啡肽样免疫反应性（βELI）显著升高。给予可乐定后，发现血浆βELI升高与血压（收缩压和舒张压）降低之间存在显著的线性相关性。可以推测，α-2肾上腺素能受体刺激引起的中枢交感神经张力降低在循环βELI升高方面发挥了作用。在另一项随机交叉研究中，多巴胺能D-2受体激动剂溴隐亭（每日5毫克）治疗后，13例临界和轻度原发性高血压患者的血浆βELI也显著升高。给予溴隐亭后，循环去甲肾上腺素和动脉血压显著下降，且血浆去甲肾上腺素水平变化与血压之间存在显著的线性相关性。溴隐亭治疗后，血浆βELI升高与血压降低之间无相关性。溴隐亭对免疫反应性β-内啡肽水平的影响可能强调了中枢交感神经活动的重要性，而不仅仅是垂体多巴胺能激动剂对β-内啡肽分泌的直接作用。
